Galectin Therapeutics Inc

Galectin Therapeutics Reports 2025 Financial Results and Provides Business Update

Galectin Therapeutics Strengthens Board of Directors with Appointment of Henry Brem, M.D.

Galectin Therapeutics to Host Virtual KOL Event to Discuss Belapectin Development Program for Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) Cirrhosis and Portal Hypertension, on March 10, 2026 at 12:00 PM ET

Galectin Therapeutics Provides Regulatory Update Following FDA Written Response and Announces an Additional $10 Million Line of Credit from Richard E. Uihlein Sufficient to Cover Expected Expenditures Through March 2027

Galectin Therapeutics Reports Financial Results for the quarter ended September 30, 2025, and Provides Business Update